Using Cystic Fibrosis Therapies for Non-Cystic Fibrosis Bronchiectasis

Wael ElMaraachli; Douglas J Conrad; Angela C C Wang

doi:10.1016/j.ccm.2015.11.005

Using Cystic Fibrosis Therapies for Non-Cystic Fibrosis Bronchiectasis

Clin Chest Med. 2016 Mar;37(1):139-46. doi: 10.1016/j.ccm.2015.11.005. Epub 2015 Dec 23.

Authors

Wael ElMaraachli¹, Douglas J Conrad², Angela C C Wang³

Affiliations

¹ Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, 200 West Arbor Drive, MC 8372, San Diego, CA 92013, USA.
² Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, 200 West Arbor Drive, MC 8372, San Diego, CA 92013, USA. Electronic address: dconrad@ucsd.edu.
³ Division of Chest and Critical Care Medicine, Scripps Clinic, 10666 North Torrey Pines Road, W203, San Diego, CA 92037, USA.

PMID: 26857775
DOI: 10.1016/j.ccm.2015.11.005

Abstract

Non-cystic fibrosis bronchiectasis (NCFB) is an increasingly prevalent disease that places a significant burden on patients and health systems globally. Although many of the therapies used to treat NCFB were originally developed as cystic fibrosis (CF) therapies, not all of them have been demonstrated to be efficacious in NCFB and some may even be harmful. This article explores the evidence for which therapeutic strategies used to treat CF have been translated into the care of NCFB. The conclusion is that therapies for adult NCFB cannot be simply extrapolated from CF clinical trials, and in some instances, doing so may actually result in harm.

Keywords: Bronchiectasis; Chest medicine; Cystic fibrosis; Non–cystic fibrosis; Treatment.

Publication types

Review

MeSH terms

Anti-Inflammatory Agents / therapeutic use*
Bronchiectasis / drug therapy*
Bronchiectasis / etiology
Bronchodilator Agents / therapeutic use*
Cystic Fibrosis / therapy*
Disease Management*
Exercise Therapy / methods*
Humans

Substances

Anti-Inflammatory Agents
Bronchodilator Agents